DEC003M in Prostate Cancer

Summary

This is an open-label, multicenter Phase 1 study of DEC003M, in patients with advanced stage prostate cancer. The study consists of a dose-escalation phase to determine the dose for expansion, followed by a dose-expansion phase to evaluate preliminary antitumor activity, safety, and pharmacokinetics.

Timeline

Start

2026-08-01

Primary completion

2029-03-31

Completion

2031-05-01

Drugs

Indications